TY - JOUR
T1 - Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
AU - Antoniotti, Carlotta
AU - Rossini, Daniele
AU - Pietrantonio, Filippo
AU - Pietrantonio, Filomena
AU - Salvatore, Lisa
AU - Lonardi, Sara
AU - Tamberi, Stefano
AU - Marmorino, Federica
AU - Moretto, Roberto
AU - Prisciandaro, Michele
AU - Tamburini, Emiliano
AU - Tortora, Giampaolo
AU - Passardi, Alessandro
AU - Bergamo, Francesca
AU - Raimondi, Alessandra
AU - Ritorto, Giuliana
AU - Borelli, Beatrice
AU - Conca, Veronica
AU - Ugolini, Clara
AU - Aprile, Giuseppe
AU - Antonuzzo, Lorenzo
AU - Gelsomino, Fabio
AU - Martinelli, Erika
AU - Pella, Nicoletta
AU - Masi, Gianluca
AU - Boni, Luca
AU - Galon, Jerome
AU - Cremolini, Chiara
PY - 2024
Y1 - 2024
N2 - Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n = 73) or FOLFOXIRI/bevacizumab plus atezolizumab (experimental group, n = 145). We present overall survival (OS) and updated outcomes according to tumor immune-related biomarkers, both in the intention-To-Treat (ITT) population and the cohort of patients with proficient mismatch repair (pMMR) tumors. Median follow-up was 45.2 months (IQR, 42.6-49.2). In t
AB - Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n = 73) or FOLFOXIRI/bevacizumab plus atezolizumab (experimental group, n = 145). We present overall survival (OS) and updated outcomes according to tumor immune-related biomarkers, both in the intention-To-Treat (ITT) population and the cohort of patients with proficient mismatch repair (pMMR) tumors. Median follow-up was 45.2 months (IQR, 42.6-49.2). In t
KW - n/a
KW - n/a
UR - http://hdl.handle.net/10807/304446
U2 - 10.1200/JCO.23.02728
DO - 10.1200/JCO.23.02728
M3 - Article
SN - 0732-183X
VL - 42
SP - 2637
EP - 2644
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
ER -
